SERAPHIN: Macitentan, novel endothelin-receptor antagonist, boosts PAH outcomes

Long-term clinical-outcomes data are in short supply for pulmonary artery hypertension drug therapies. Regulators are now looking at macitentan, which is making its case largely on the strength of the three-year, clinical-endpoint-driven SERAPHIN trial.
Source: theHeart.org - Category: Cardiology Source Type: news